Barbara-Jean Anne Bormann-Kennedy, serving as a director at Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), completed a stock sale on June 4, 2026. The transaction involved the divestment of 16,000 shares of the company's common stock. The total value of this sale was recorded at $97,507. The shares were sold at varying prices within a range of $5.970 to $6.170 per share. This specific sale was carried out under the guidelines of a Rule 10b5-1 trading plan that Ms. Bormann-Kennedy established on September 12, 2025. At the time of this reporting, XERS shares were trading at $6.18, reflecting a 39% return over the preceding twelve-month period.
On the identical date of June 4, 2026, Ms. Bormann-Kennedy also received equity compensation from the company. She acquired 24,193 shares of common stock through a restricted stock unit grant. These particular shares were obtained at no cost to her. The vesting schedule for these restricted shares is tied to specific conditions. The shares are set to vest upon the earlier of two dates: June 4, 2026, or the date of the company's next annual meeting of stockholders. This vesting is strictly contingent upon her continued service with the company.
Furthermore, the director was granted 32,996 stock options. These options provide her with the right to purchase an equivalent number of common shares at an exercise price of $6.15 per share. The expiration date for these stock options is set for June 4, 2036. Similar to the restricted stock units, these options will vest in full upon the earlier of June 4, 2026, or the date of the next annual meeting of stockholders, subject to her continued service.
Following the completion of these transactions, Ms. Bormann-Kennedy's direct holdings in the company consist of 150,693 shares of common stock. In addition to the shares, she holds 32,996 stock options. The biopharma company, valued at $1.06 billion, has reported profitability over the last twelve months. According to InvestingPro analysis, XERS appears undervalued at current levels. Investors seeking deeper insights can access a comprehensive Pro Research Report covering XERS and 1,400+ other US equities.
In other recent news, Xeris Biopharma reported a 38% increase in total revenue for Q1 2026, reaching $83.1 million. Despite slightly missing revenue forecasts, the company exceeded expectations with an earnings per share (EPS) of $0.01. These financial results highlight the company's solid growth trajectory. Analysts had projected lower earnings, making the EPS achievement notable. The company's performance reflects its ability to surpass profit expectations even when revenue projections are not fully met. This development comes amidst a backdrop of ongoing evaluations by financial analysts. While no recent upgrades or downgrades were noted, the financial results may influence future analyst assessments. These recent developments underscore the company's financial resilience and operational effectiveness.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Is XERS a bargain right now? The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for XERS plus thousands of other stocks and find your next hidden gem with massive upside. See Undervalued Stocks